BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales results of INGREZZA® (valbenazine) for 2021, and key clinical development milestones for 2022 and 2023.

Blueprint Medicines Corporation announced that, effective on January 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 9,725 shares of its common stock and an aggregate of 4,862 restricted stock units to seven new employees under Blueprint Medicines’ 2020 Inducement Plan.

Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101.

Xencor, Inc. announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.

Tiziana Life Sciences, a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference.

QIAGEN N.V. announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million.

GT Biopharma, Inc. announced that the Compensation Committee of its Board of Directors approved, on December 31, 2021, the following equity compensation awards as inducements material to the following employees’ acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635.

ICU Medical Inc. announced that it has completed its acquisition of Smiths Medical from Smiths Group plc.

BD, a leading global medical technology company, announced that in the interest of the health and safety of its shareholders, directors, officers, employees and meeting attendees in light of the current and ongoing COVID-19 pandemic, the format of its 2022 Annual Meeting of Shareholders has been changed to a virtual-only meeting.